AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
These triazine-based bis-sulfonamide derivatives represent a promising therapeutic scaffold for the development of next-generation bacterial DNA topoisomerase inhibitors and are evaluated for their in vitro antibacterial efficacy and non-cytotoxic profiles.
Promising compounds like SBB-2, SBB-3, SBB-5, SBB-6, and SBB-7 exhibit favourable physicochemical properties, high drug-likeness, solubility, and a non-toxic profile, making them strong candidates for further development of a promising drug.
The integrated experimental and computational results identified compound 3b as the most promising member of the present series, particularly with respect to antibacterial activity, while the comparatively limited antifungal activity indicates the need for further structural optimization.
Pyrazole-1,3,4-thiadiazine-linked isoxazole derivatives, specifically 6n and 6o, are identified as potential candidates for the development of novel antibacterial and antibiofilm drugs.
The seamless integration of green synthesis, computational modeling, and biological validation highlights these 2-amino-3,5-dicarbonitrile-6-sulfanylpyridine hybrids as compelling lead candidates for multi-target therapeutic applications against invasive bacterial and fungal infections.
It is suggested that thiazolo[5,4-b]pyridine–sulfonamide hybrids represent promising scaffolds for the development of new antimicrobial agents.
Mechanistic studies indicated that compounds 5c and 5f inhibited cancer cell growth predominantly by inducing apoptosis rather than cell cycle arrest, indicating favourable selectivity.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.